| abstract |
The present invention provides a quinazoline-7-ether derivative, in particular a 4-anilino-6-butenylamino-quinazoline-7-ether derivative, which is a receptor protein tyrosine kinase (RTK) Inhibitors. Such compounds are useful in the treatment of diseases and conditions involving RTK activity, such as hyperproliferative diseases such as cancer. The invention also provides methods of preparing such quinazoline derivatives and methods of using the same as a therapeutic agent, either alone or in combination. |